As MMP9 is thought to play a key role in tumor invasion and metastasis, we proceeded to test whether any of the seven EDS inhibitory antibodies would slow down metastasis of an invasive breast cancer line HT-1080 overexpressing MMP9. Here, MMP9 is linked to invasive breast carcinoma.